Evercore ISI analyst Vijay Kumar raised the firm’s price target on Penumbra (PEN) to $340 from $286 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have “set the stage for a 2026 Tools play,” the analyst tells investors. In MedTech, the firm’s survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes “have bears watching,” the analyst added.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Penumbra price target raised to $370 from $320 at BofA
- Penumbra price target raised to $370 from $312 at Truist
- Penumbra: Accelerating Growth, Margin Upside, and 2026+ Catalysts Support Overweight (Buy) Rating
- Penumbra upgraded to Overweight from Neutral at JPMorgan
- Penumbra price target raised to $355 from $325 at RBC Capital